Aspergillus Antibodies: Association with Severity of Disease in Patients Suffering from Asthma
DOI:
https://doi.org/10.51253/pafmj.v75iSUPPL-5.7113Keywords:
Anti Aspergillus Antibodies, Asthma, IgG, Severity of Disease.Abstract
Objective: To determine the association of anti-aspergillus antibodies and other socio-demographic factors with severity of disease among patients suffering from asthma.
Study Design: Comparative cross-sectional study.
Place and Duration of Study: Pulmonology Department, Pak Emirates Military Hospital, Rawalpindi Pakistan, from Dec 2020 to May 2021.
Methodology: One hundred and fifty patients of asthma diagnosed for more than one year by a consultant respiratory physician were included in the study. Severity of asthma was assessed at the time of initial assessment and classed as mild, moderate or severe on the basis of symptoms and lung function tests. Baseline Laboratory investigations along with serum for anti-aspergillus antibodies were sent as well at the same time. Association of presence of aspergillus antibodies in serum along with their demographic factors was assessed with severity of illness in our study participants.
Results: Out of 150 patients of asthma, 65(43.3%) had mild illness, 44(29.3%) had moderate and 41(27.3%) had severe illness. Mean age of the study participants was 41.232±8.91 years. 115(76.7%) were positive for IgG anti-aspergillus antibodies while 35(23.3%). Presence of IgG anti-aspergillus antibodies had statistically significant relationship with sever asthmatic illness in our study population (p-value<0.001).
Conclusion: More than quarter of the study participants had severe form of asthmatic illness in this study and presence of IgG anti-aspergillus antibodies emerged as a factor strongly associated with severity of illness among patients of persistent asthma included in our study.
Downloads
References
1. Caminati M, Vultaggio A, Matucci A, Senna G, Almerigogna F, Bagnasco D, et al. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med 2021; 176(#): 106261.
https://doi.org/10.1016/j.rmed.2020.106261
2. Razzaq S, Nafees AA, Rabbani U, Irfan M, Naeem S, Khan MA et al. Epidemiology of asthma and associated factors in an urban Pakistani population: adult asthma study-Karachi. BMC Pulm Med 2018; 18(1): 184.
https://doi.org/10.1186/s12890-018-0753-y
3. Hossny E, Caraballo L, Casale T, El-Gamal Y, Rosenwasser L. Severe asthma and quality of life. World Allergy Organ J 2017; 10(1): 28.
https://doi.org/10.1186/s40413-017-0159-y4
4. Stubbs MA, Clark VL, McDonald VM. Living well with severe asthma. Breathe (Sheff) 2019; 15(2): e40-e49.
https://doi.org/10.1183/20734735.0165-2019
5. Calciano L, Corsico AG, Pirina P, Trucco G, Jarvis D, Janson C et al. Assessment of asthma severity in adults with ever asthma: A continuous score. PLoS One 2017; 12(5): e0177538.
https://doi.org/10.1371/journal.pone.0177538
6. Kang HR, Song HJ, Nam JH, Hong SH, Yang SY, Ju S, et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open 2018; 8(3): e020825.
https://doi.org/10.1136/bmjopen-2017-020825
7. Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Med Mycol 2011; 3(Suppl 1): S150-157.
https://doi.org/10.3109/13693786.2010.504752
8. Kozlova YI, Frolova EV, Filippova LV, Uchevatkina AE, Aak OV, Klimko NN. Allergic bronchopulmonary aspergillosis in patients with asthma: Results of a prospective study. Ter Arkh 2017; 89(8): 13-16.
https://doi.org/10.17116/terarkh201789813-16
9. Kwizera R, Musaazi J, Meya DB, Worodria W, Bwanga F, Kajumbula H, et al. Burden of fungal asthma in Africa: A systematic review and meta-analysis. PLoS One 2019; 14(5): e0216568. https://doi.org/10.1371/journal.pone.0216568
10. Zubairi AB, Azam I, Awan S, Zafar A, Imam AA. Association of airborne Aspergillus with asthma exacerbation in Southern Pakistan. Asia Pac Allergy 2014; 4(2): 91-98.
https://doi.org/10.5415/apallergy.2014.4.2.91
11. Maurya V, Gugnani HC, Sarma PU, Madan T, Shah A. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest 2005; 127(4): 1252-1259.
https://doi.org/10.1378/chest.127.4.1252
12. Pollart SM, Elward KS. Overview of changes to asthma guidelines: diagnosis and screening. Am Fam Physician 2009; 79(9): 761-767.
13. Guo Y, Bai Y, Yang C, Gu L. Evaluation of Aspergillus IgG, IgM antibody for diagnosing in chronic pulmonary aspergillosis: A prospective study from a single center in China. Medicine (Baltimore) 2019; 98(16): e15021.
https://doi.org/10.1097/MD.0000000000015021
14. van Tilburg Bernardes E, Gutierrez MW, Arrieta MC. The Fungal Microbiome and Asthma. Front Cell Infect Microbiol 2020; 10(3): 583418. https://doi.org/10.3389/fcimb.2020.583418
15. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27(3): 615-626.
https://doi.org/10.1183/09031936.06.00074705
16. Khanbabaee G, Enayat J, Chavoshzadeh Z, Tabatabaei SA, Gorji FA, Rezaei N. Serum level of specific IgG antibody for aspergillus and its association with severity of asthma in asthmatic children. Acta Microbiol Immunol Hung 2012; 59(1): 43-50. https://doi.org/10.1556/AMicr.59.2012.1.5
17. Agarwal R. Severe asthma with fungal sensitization. Curr Allergy Asthma Rep 2011; 11(5): 403-413.
https://doi.org/10.1007/s11882-011-0217-4
18. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013; 51(4): 361-370.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zahra Asif Sukhera, Muhammad Zill-e-Hamayun Mirza, Ibrahim Zafar Gondal, Asif Mumtaz Sukhera, Rizwan Azam, Zainab Asif Sukhera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
